scholarly journals Stem Cell Growth Factor Beta

2020 ◽  
Author(s):  
Keyword(s):  
Stem Cell ◽  
Growth Factor ◽  
Cell Growth ◽  
Growth Factor Beta ◽  
Stem Cell Growth Factor

scholarly journals Serum Stem Cell Growth Factor Beta for the Prediction of Therapy Response in Hepatocellular Carcinoma

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Caecilia H. C. Sukowati ◽  
Riccardo Patti ◽  
Devis Pascut ◽  
Rusdina B. Ladju ◽  
Paola Tarchi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Stem Cell ◽  
Growth Factors ◽  
Growth Factor ◽  
Cell Growth ◽  
Disease Free Survival ◽  
Chronic Inflammatory Response ◽  
Treatment Type ◽  
Growth Factor Beta ◽  
Stem Cell Growth Factor

Introduction. Chronic inflammatory response is one of major contributors in the development of hepatocellular carcinoma (HCC). Inflammatory molecules, such as cytokines and growth factors in the circulation, can be useful in the diagnosis and prognosis of the patients. The stem cell growth factor beta (SCGFβ), a newly found protein, is a secreted sulfated glycoprotein and it functions as a growth factor for primitive hematopoietic progenitor cells. The level of SCGFβ had been reported to be elevated in several cancer types. However, there is very few or even no information on this protein in the study of HCC, even more in clinical studies. Methods. A multiplex immunoassay panel of 48 cytokines and growth factors were utilized to screen 68 sera from 29 HCC patients at pretreatment (T0), 1 month (T1), and 6 months (T6) after treatment by either radiofrequency ablation (RF) or transarterial chemoembolization (TACE). Treatment response was evaluated according to mRECIST criteria. Results. Immunoassay screening showed that the levels of IL-17, CTACK, TNFα, IL-2Rα, IL-8, and SCGFβ were different in Complete Responders (CR) and Nonresponders (NR) groups. At T0 and T1, the SCGFβ level was significantly the highest in NR (23.8 and 40.7 ng/mL, respectively), followed by early recurrence (25.4 and 25.0 ng/mL), and CR (6.7 and 5.3 ng/mL), independently from HCV, stages, and treatment type. Low basal SCGFβ level was associated with longer disease-free survival compared to high SCGFβ. Conclusion. In this study, for the first time, we demonstrate that the high level of serum SCGFβ at pre- and posttreatment is associated with HCC nonresponsiveness.

Prognostic value of circulating levels of stem cell growth factor beta (SCGF beta) in patients with Chagas’ disease and idiopathic dilated cardiomyopathy

Cytokine ◽  
2013 ◽  
Vol 61 (3) ◽  
pp. 728-731 ◽  
Author(s):  
Yong Wang ◽  
Adnan Khan ◽  
Silvia Heringer-Walther ◽  
Heinz-Peter Schultheiss ◽  
Maria da Consolação V. Moreira ◽  
...  
Keyword(s):  
Stem Cell ◽  
Growth Factor ◽  
Cell Growth ◽  
Dilated Cardiomyopathy ◽  
Chagas Disease ◽  
Prognostic Value ◽  
Idiopathic Dilated Cardiomyopathy ◽  
Growth Factor Beta ◽  
Circulating Levels ◽  
Stem Cell Growth Factor

scholarly journals Stem cell growth factor receptor in canine vs. feline osteosarcomas

2016 ◽  
Vol 12 (4) ◽  
pp. 2485-2492 ◽  
Author(s):  
Birgitt Wolfesberger ◽  
Andrea Fuchs-Baumgartinger ◽  
Juraj Hlavaty ◽  
Florian R. Meyer ◽  
Martin Hofer ◽  
...  
Keyword(s):  
Stem Cell ◽  
Growth Factor ◽  
Cell Growth ◽  
Growth Factor Receptor ◽  
Stem Cell Growth Factor ◽  
Cell Growth Factor Receptor

Application of stem cell/growth factor system, as a multimodal therapy approach in regenerative medicine to improve cell therapy yields

2014 ◽  
Vol 173 (1) ◽  
pp. 12-19 ◽  
Author(s):  
Fatemeh Pourrajab ◽  
Mojtaba Babaei Zarch ◽  
Mohammad Baghi Yazdi ◽  
Abolfazl Rahimi Zarchi ◽  
Abbas Vakili Zarch
Keyword(s):  
Stem Cell ◽  
Growth Factor ◽  
Cell Growth ◽  
Regenerative Medicine ◽  
Cell Therapy ◽  
Multimodal Therapy ◽  
Therapy Approach ◽  
Factor System ◽  
Stem Cell Growth Factor

Dickkopf 1 (Dkk1) Regulates Hematopoietic Stem Cell Regeneration

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 1200-1200
Author(s):  
Heather A Himburg ◽  
Phuong L Doan ◽  
Xiao Yan ◽  
Mamle Quarmyne ◽  
Liman Zhao ◽  
...  
Keyword(s):  
Stem Cell ◽  
Growth Factor ◽  
Cell Growth ◽  
Hematopoietic Stem Cell ◽  
Systemic Administration ◽  
Hematopoietic Stem ◽  
University Patents ◽  
Duke University ◽  
Osteolineage Cells ◽  
Stem Cell Growth Factor

Abstract Bone marrow endothelial cells (BM ECs) have been shown to regulate HSC regeneration following myelosuppression. The role of osteolineage cells in regulating HSC regeneration remains less well understood. Here, we show that deletion of the pro-apoptotic genes, Bak and Bax, in osterix (Osx)-expressing osteoprogenitor cells promoted HSC regeneration and hematopoietic radioprotection of mice following total body irradiation (TBI). We identified Dkk1 to be enriched in the BM of radioprotected OsxCre;Bak1-/-;BaxFL/- mice and found that Bak /Bax-deficient osteolineage cells expressed increased levels of Dkk1 compared to Bax-expressing osteolineage cells (p=0.003). Treatment of irradiated BM HSCs with DKK1 in vitro significantly increased the recovery of phenotypic HSCs (p=0.0002), colony forming cells (CFCs)(p=0.003) and long-term repopulating HSCs compared to control cultures (p=0.009). Systemic administration of Dkk1 to lethally irradiated C57Bl6 mice accelerated the recovery of mature blood counts (p=0.008), BM HSCs (p=0.008) and progenitor cells (p=0.007). Furthermore, survival after lethal irradiation was markedly increased in Dkk1 treated mice (93%) compared to saline controls (27%; p=0.0004). Conversely, systemic administration of anti-Dkk1 antibody significantly delayed recovery of BM HSCs (p=0.002), peripheral white blood cells (p=0.0004), neutrophils (p<0.0001) and lymphocytes (p=0.002) in irradiated mice compared to irradiated, control mice. Dkk1 promoted HSC regeneration via suppression of reactive oxygen species (ROS) and inhibition of caspase activation in HSCs following irradiation. Dkk1 represents a novel, osteoprogenitor cell-derived paracrine factor which is necessary for normal hematopoietic regeneration following irradiation and can be therapeutically delivered to accelerate hematopoietic reconstitution. Disclosures Himburg: Duke University: Patents & Royalties: Patent Application for use of Pleiotrophin as a hematopoietic stem cell growth factor. Chute:C2 Regenerate: Equity Ownership; Duke University: Patents & Royalties: Application to use PTN as growth factor as hematopoietic stem cell growth factor.

A recurrent deletion in the KIT (mast/stem cell growth factor receptor) proto-oncogene is a frequent cause of human piebaldism

1993 ◽  
Vol 2 (9) ◽  
pp. 1499-1500 ◽  
Author(s):  
R.A. Spritz ◽  
Stuart A. Holmes ◽  
Susan Z. Berg ◽  
James J. Nordlund ◽  
Kazuyoshl Fukal
Keyword(s):  
Stem Cell ◽  
Growth Factor ◽  
Cell Growth ◽  
Growth Factor Receptor ◽  
Stem Cell Growth Factor ◽  
Cell Growth Factor Receptor ◽  
Recurrent Deletion

scholarly journals A degradable, bioactive, gelatinized alginate hydrogel to improve stem cell/growth factor delivery and facilitate healing after myocardial infarction

2012 ◽  
Vol 79 (5) ◽  
pp. 673-677 ◽  
Author(s):  
Domenico G. Della Rocca ◽  
Bradley J. Willenberg ◽  
Leonardo F. Ferreira ◽  
Prateek S. Wate ◽  
John W. Petersen ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Stem Cell ◽  
Growth Factor ◽  
Cell Growth ◽  
Growth Factor Delivery ◽  
Alginate Hydrogel ◽  
Stem Cell Growth Factor

scholarly journals Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome

2017 ◽  
Vol 13 (4) ◽  
pp. 1187-1193 ◽  
Author(s):  
Yuna Chai ◽  
Yusheng Huang ◽  
Hongmei Tang ◽  
Xing Tu ◽  
Jianbo He ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Stem Cell ◽  
Growth Factor ◽  
Cell Growth ◽  
Irritable Bowel ◽  
Factor C ◽  
Stem Cell Growth Factor
Sign in / Sign up

Export Citation Format

Share Document